Clinical research progress of immunotherapy for nasopharyngeal carcinoma
10.3760/cma.j.cn371439-20230120-00060
- VernacularTitle:鼻咽癌免疫治疗的临床研究进展
- Author:
Anqin GU
1
;
Jinhua LONG
;
Feng JIN
Author Information
1. 贵州医科大学临床医学院肿瘤教研室，贵阳 550000
- Keywords:
Nasopharyngeal neoplasms;
Immunotherapy;
Immune checkpoint inhibitors;
Immunotherapy, adoptive
- From:
Journal of International Oncology
2023;50(5):299-303
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy mainly uses the effector units of the body's immune system to overcome the immune escape or adaptive immune resistance of tumors, accurately identify and remove tumor cells, and normalize or enhance the function of the immune system, which mainly includes cytokine therapy, immune checkpoint inhibition therapy, adoptive cell immunotherapy, tumor vaccine and antibody targeted therapy. The immune characteristics of nasopharyngeal carcinoma make the patients potentially suitable for immunotherapy or combined therapy with radiotherapy and chemotherapy. In recent years, PD-1 inhibitors alone and in combination with chemotherapy have shown good anti-tumor activity and safety in the treatment of recurrent/metastatic nasopharyngeal carcinoma. The incorporation of immune checkpoint inhibitors into the treatment paradigms of nasopharyngeal carcinoma has become a clinical research hot spot.
